Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 6/20 | 0.69 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.69 |
| ▸ | PRKCG | P05129 | 2/20 | 0.67 |
| ▸ | CA9 | Q16790 | 1/20 | 0.67 |
| ▸ | CETP | P11597 | 1/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12557822 | 1.00 | NT5E (0.69) | NT5EPRKCDPRKCGCA9CETP | |
| SCHEMBL9131707 | 1.00 | NT5E (0.69) | NT5EPRKCDPRKCGCA9CETP | |
| SCHEMBL10214444 | 1.00 | NT5E (0.69) | NT5EPRKCDPRKCGCA9CETP | |
| SCHEMBL14124010 | 1.00 | NT5E (0.69) | NT5EPRKCDPRKCGCA9CETP | |
| SCHEMBL9130088 | 1.00 | NT5E (0.69) | NT5EPRKCDPRKCGCA9CETP | |
| SCHEMBL9129432 | 1.00 | NT5E (0.69) | NT5EPRKCDPRKCGCA9CETP | |
| SCHEMBL10214496 | 1.00 | NT5E (0.69) | NT5EPRKCDPRKCGCA9CETP | |
| SCHEMBL14156586 | 1.00 | NT5E (0.69) | NT5EPRKCDPRKCGCA9CETP | |
| SCHEMBL9129051 | 0.93 | GPBAR1 (0.67) | — | |
| SCHEMBL10214539 | 0.93 | NT5E (0.71) | NT5EPRKCDPRKCGCETPPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105203-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105203-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, CCL11 | NT5E 573/4885PRKCD 3851/4885PRKCG 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.